| scholarly article | Q13442814 |
| P50 | author | James Moon | Q43171837 |
| P2093 | author name string | Yuchen Fan | |
| P2860 | cites work | Zika virus. I. Isolations and serological specificity | Q22240545 |
| Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? | Q22330682 | ||
| Potential sexual transmission of Zika virus | Q22330722 | ||
| Factors affecting the escape of Francisella tularensis from the phagolysosome | Q57441686 | ||
| A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae | Q58860165 | ||
| Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres | Q71701792 | ||
| Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin | Q73978913 | ||
| Protection of monkeys against Shiga toxin induced by Shiga toxin-liposome conjugates | Q74138936 | ||
| Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations | Q74275312 | ||
| Induction of protection against oral infection with cytotoxin-producing Escherichia coli O157:H7 in mice by shiga-like toxin-liposome conjugate | Q74846036 | ||
| Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation | Q78036046 | ||
| Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles | Q84673881 | ||
| Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice | Q84938205 | ||
| Prediction of T cell epitopes of Brucella abortus and evaluation of their protective role in mice | Q85546395 | ||
| Cell mediated immune response after challenge in Omp25 liposome immunized mice contributes to protection against virulent Brucella abortus 544 | Q85807591 | ||
| Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults | Q87419407 | ||
| Emerging targets and novel approaches to Ebola virus prophylaxis and treatment | Q24597625 | ||
| Encephalitic alphaviruses | Q24655184 | ||
| Ebolavirus Evolution: Past and Present | Q26777336 | ||
| Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy | Q26782566 | ||
| Protecting against plague: towards a next-generation vaccine | Q26823422 | ||
| The staphylococcal enterotoxin (SE) family: SEB and siblings | Q26830220 | ||
| Development of Burkholderia mallei and pseudomallei vaccines | Q26861271 | ||
| Vaccines against invasive Salmonella disease: current status and future directions | Q27007088 | ||
| Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection | Q27026551 | ||
| Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens | Q27310007 | ||
| Synthetic Nanoparticles for Vaccines and Immunotherapy | Q28085375 | ||
| Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei | Q28299584 | ||
| Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei | Q28302368 | ||
| Public health investigation after the discovery of ricin in a South Carolina postal facility | Q28395591 | ||
| Pathology and pathogenesis of bioterrorism-related inhalational anthrax | Q28395786 | ||
| Intranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challenge | Q28743895 | ||
| The global burden of typhoid fever | Q29619215 | ||
| Recombinant L7/L12 protein entrapping PLGA (poly lactide-co-glycolide) micro particles protect BALB/c mice against the virulent B. abortus 544 infection. | Q30374295 | ||
| Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain | Q30411506 | ||
| Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation | Q31152190 | ||
| Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice | Q32066443 | ||
| Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine | Q33258307 | ||
| Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice. | Q33282108 | ||
| Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge | Q33284583 | ||
| pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides | Q33703757 | ||
| Present and future therapeutic strategies for melioidosis and glanders | Q33797791 | ||
| Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases | Q33847904 | ||
| Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense | Q33901607 | ||
| Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses | Q33987611 | ||
| Dissolving polymer microneedle patches for influenza vaccination | Q34049972 | ||
| Killed oral cholera vaccines: history, development and implementation challenges | Q34087755 | ||
| Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages | Q34145815 | ||
| Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine | Q34157315 | ||
| What next for botulism vaccine development? | Q34343808 | ||
| Biomaterials for nanoparticle vaccine delivery systems | Q34345012 | ||
| Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells | Q34345308 | ||
| Mucosal immunity and vaccines | Q34409172 | ||
| Efficacy of a tetravalent dengue vaccine in children in Latin America. | Q34446032 | ||
| Post-licensure deployment of oral cholera vaccines: a systematic review | Q34456242 | ||
| Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates | Q34468847 | ||
| Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease | Q34487028 | ||
| Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial | Q34488529 | ||
| Vibrio cholerae: lessons for mucosal vaccine design | Q34562952 | ||
| Rapid vaccination using an acetalated dextran microparticulate subunit vaccine confers protection against triplicate challenge by bacillus anthracis. | Q34564854 | ||
| Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge | Q34583832 | ||
| Brucellosis: the case for live, attenuated vaccines | Q34612868 | ||
| Towards a Brucella vaccine for humans | Q34617109 | ||
| Ricin poisoning: a comprehensive review | Q34651243 | ||
| A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge. | Q34700706 | ||
| Ebola virus-like particles protect from lethal Ebola virus infection | Q34792924 | ||
| Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses | Q34802680 | ||
| A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery | Q34938244 | ||
| Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine | Q35007523 | ||
| A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei | Q35088366 | ||
| Virus-like particles activate type I interferon pathways to facilitate post-exposure protection against Ebola virus infection | Q35125834 | ||
| Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates? | Q35173777 | ||
| Advances in virus-like particle vaccines for filoviruses | Q35300029 | ||
| Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres | Q35426971 | ||
| Modulating antibacterial immunity via bacterial membrane-coated nanoparticles | Q35447934 | ||
| Passive and active vaccination strategies to prevent ricin poisoning | Q35459324 | ||
| Identification of the major steps in botulinum toxin action | Q35639122 | ||
| Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores | Q35666215 | ||
| Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction | Q35709003 | ||
| Epidemiology of viral encephalitis in 2011. | Q37908607 | ||
| Ricin vaccine development | Q37909206 | ||
| New-generation vaccines against cholera | Q37953796 | ||
| Microneedle technologies for (trans)dermal drug and vaccine delivery | Q37985278 | ||
| E. coli O157:H7 and other toxigenic strains: the curse of global food distribution | Q38011614 | ||
| Flaviviruses and flavivirus vaccines | Q38017388 | ||
| Vaccines against botulism | Q38018405 | ||
| Bovine innate and adaptive immune responses against Escherichia coli O157:H7 and vaccination strategies to reduce faecal shedding in ruminants | Q38053703 | ||
| Recent progress towards development of a Shigella vaccine | Q38068954 | ||
| The state-of-the-art of approved and under-development cholera vaccines | Q38120924 | ||
| Applications of nanotechnology for immunology | Q38123937 | ||
| Anthrax vaccines: present status and future prospects. | Q38132268 | ||
| Glanders: an overview of infection in humans | Q38134214 | ||
| A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available | Q38184218 | ||
| Oral delivery of nanoparticle-based vaccines. | Q38243119 | ||
| An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children | Q38284501 | ||
| Delivery strategies to enhance oral vaccination against enteric infections. | Q38393940 | ||
| Plague vaccines: current developments and future perspectives | Q38514208 | ||
| Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines | Q38549298 | ||
| Polymeric micro/nanoparticles: Particle design and potential vaccine delivery applications | Q38564510 | ||
| Dependence of ricin toxoid vaccine efficacy on the structure of poly(lactide-co-glycolide) microparticle carriers | Q38573856 | ||
| Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo | Q39158198 | ||
| Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein | Q40177646 | ||
| Recent advances in the field of Salmonella Typhi vaccines | Q40356880 | ||
| Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A. | Q40633916 | ||
| Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine | Q41021296 | ||
| Effect of nanovaccine chemistry on humoral immune response kinetics and maturation | Q41382022 | ||
| Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours | Q41389065 | ||
| Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens | Q41402264 | ||
| Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles | Q41437305 | ||
| Public health assessment of potential biological terrorism agents | Q42535925 | ||
| Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. | Q43012213 | ||
| Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice | Q43623067 | ||
| An approach to a cold chain free oral cholera vaccine: in vitro and in vivo characterization of Vibrio cholerae gastro-resistant microparticles | Q43921493 | ||
| Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles | Q44100330 | ||
| The immunogenic characteristics associated with multivalent display of Vi polysaccharide antigen using biodegradable polymer particles | Q44275731 | ||
| Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin-producing Escherichia coli to Caco-2 cells by oral immunization with liposomes | Q44311804 | ||
| Stretch-Triggered Drug Delivery from Wearable Elastomer Films Containing Therapeutic Depots. | Q44858972 | ||
| Immune response with biodegradable nanospheres and alum: studies in rabbits using staphylococcal enterotoxin B-toxoid | Q46450224 | ||
| Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults | Q47225463 | ||
| Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. | Q50962149 | ||
| Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. | Q51270683 | ||
| Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination. | Q51723404 | ||
| Other biologic toxin bioweapons: ricin, staphylococcal enterotoxin B, and trichothecene mycotoxins | Q35810753 | ||
| The history of ricin, abrin and related toxins | Q35859608 | ||
| Cationic liposomes extend the immunostimulatory effect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/c mice | Q35940681 | ||
| Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens | Q35961159 | ||
| Whole-animal imaging and flow cytometric techniques for analysis of antigen-specific CD8+ T cell responses after nanoparticle vaccination | Q35970758 | ||
| Prospects for immunisation against Marburg and Ebola viruses | Q36088118 | ||
| Vaccination strategies for Francisella tularensis | Q36140889 | ||
| Particulate delivery systems for biodefense subunit vaccines | Q36151625 | ||
| Vaccines against the category B toxins: Staphylococcal enterotoxin B, epsilon toxin and ricin. | Q36151654 | ||
| Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development | Q36159276 | ||
| Microneedles for drug and vaccine delivery | Q36164749 | ||
| Glycoconjugate vaccine strategies for protection against invasive Salmonella infections | Q36184367 | ||
| Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia. | Q36191199 | ||
| Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus | Q36239796 | ||
| Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery | Q36331113 | ||
| Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity | Q36368527 | ||
| Mucosal vaccines: the promise and the challenge | Q36402244 | ||
| Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. | Q36445263 | ||
| Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road | Q36844719 | ||
| A history of the development of Brucella vaccines | Q36938722 | ||
| TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis | Q37120117 | ||
| Protection from pneumonic infection with burkholderia species by inhalational immunotherapy | Q37145069 | ||
| Engineering nano- and microparticles to tune immunity | Q37205125 | ||
| Antimicrobial resistance in typhoidal and nontyphoidal salmonellae | Q37251632 | ||
| Nanoparticle-detained toxins for safe and effective vaccination | Q37426321 | ||
| Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles | Q37571922 | ||
| Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague | Q37588454 | ||
| Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination | Q37603557 | ||
| Cationic liposomes as vaccine adjuvants | Q37867105 | ||
| Progress on plague vaccine development | Q37889155 | ||
| P433 | issue | 1 | |
| P921 | main subject | emerging communicable disease | Q609748 |
| bioterrorism | Q854975 | ||
| P304 | page(s) | e1403 | |
| P577 | publication date | 2016-04-01 | |
| P1433 | published in | Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology | Q24056192 |
| P1476 | title | Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens | |
| P478 | volume | 9 |
| Q56889010 | Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases |
| Q39271088 | Biomaterial strategies for generating therapeutic immune responses |
| Q92726819 | Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis |
| Q88493495 | Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy |
| Q92047320 | Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases |
| Q38157955 | Knowledge and attitudes towards Zika virus among medical students in King Abdulaziz University, Jeddah, Saudi Arabia |
| Q93191860 | Multilamellar Vaccine Particle Elicits Potent Immune Activation with Protein Antigens and Protects Mice against Ebola Virus Infection |
| Q38404208 | Toward a Single-Dose Vaccination Strategy with Self-Encapsulating PLGA Microspheres |
| Q59350217 | Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses |
Search more.